Memorial Sloan-Kettering Cancer Center

Slides:



Advertisements
Similar presentations
Updates on Breast Diseases: What clinicians need to know from pathologists Preah Bat Norodom Sihanouk Hopsital, 22 April 2009 Monirath Hav, MD, Ph.D. fellow.
Advertisements

HELIOS Kliniken Leipziger Land Folie: 1 K. Kuhnt D. Schulz NESA DAYS 2006 Positive margins and early postop potency after Nerve-sparing ELRP Kai Kuhnt.
50 Vs 50 A Comparison of the Oncologic Outcomes of Retropubic Prostatectomy and Robotic Prostatectomy Chris Ogden Tim Christmas Jordan Durrant Khalid A.
NPCA data collection on men undergoing radical surgery for prostate cancer Paul Cathcart, NPCA Urology Project Coordinator.
PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.
Advanced Stage Prostate Cancer Management Michael E. Karellas Assistant Professor of Urologic Oncology May 15, 2010.
Grade 1 (almost) never assigned Grade 2 rarely assigned on TURP and RP (exceptionally rare on biopsy)
Is the BRAF V600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer? The American Journal of Surgery.
In biochemical recurrence after curative treatment of prostate cancer, Choline PET/CT 1- has a detection rate of 10-20% when PSA: 1-2 ng/ml 2- has a detection.
Steven Joniau Filip Ameye
Objectives: Our first segment focused in the anatomy and functions of the prostate gland, to get a clear understanding of the male Genito-Urinary System.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Treatment options for locally recurrent Prostate Cancer Giuseppe Simone Mediterranean School of Oncology Roma
Modern Management of Prostate Cancer With Active Surveillance PROSTATE CANCER SYMPOSIUM NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE SEPTEMBER 10,
Howard M. Sandler, MD University of Michigan Medical School
The Ratio of Lymph Node to Primary Tumor SUV on PET/CT Accurately Predicts Nodal Malignancy in Non- Small Cell Lung Cancer Malcolm Mattes, Salma Ahsanuddin,
Mark L. Merlin, M.D. Radiotherapy Clinics of Georgia 7/14/2010 The Role of Radiation Therapy in the Management of Prostate Cancer.
Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.
Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.
Postoperative Radiotherapy for Patients with Stage II or III Nonsmall Cell Lung Cancer treated with Sublobar Resections: A SEER Registry Analysis Scott.
INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,
CASE 1 65-year-old man No other diseases or previous surgeries July 2005: PSA 11.5 ng/ml; F/T: 9% After prostate biopsy revealing adenocarcinoma: RETROPUBIC.
Protocols for Advanced Prostate Cancer and/or Local Failure After Radical Prostatectomy Isaac Powell, MD.
Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results.
Poster Title ABSTRACT #59 Cell cycle progression genes differentiate indolent from aggressive prostate cancer. Steven Stone 1 Jack Cuzick 2, Julia Reid.
TNM Staging: Prostate TONYA BRANDENBURG, MHA, CTR KENTUCKY CANCER REGISTRY.
Supplemental Digital Content Figure 1A A Academic/Research Program Extent of Lung Resection No. of SubjectEventCensored Median Survival (95% CI)60 mo Survival.
MRI IN PROSTATE CANCER MAHYAR GHAFOORI M.D. Associate Professor of Radiology Tehran University Of Medical Sciences.
Collaborative Staging for Colon Site Specific Factors Tonya Brandenburg, MHA, CTR QA Manager Abstracting and Coding Kentucky Cancer Registry.
Postsurgical Risk Factors for Prostate Cancer Mortality Slideset on: Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality.
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer Anna Bill-Axelson, M.D., Lars Holmberg, M.D., Ph.D., Mirja Ruutu, M.D., Ph.D., Michael.
Assessing Quality of Pathology Reporting: The Case of Tongue Cancer Lihua Liu 1, PhD Wesley Y. Naritoku 2, MD, PhD Juanjuan Zhang 1, MS Lenard Berglund.
Should Elderly Patients Undergo Additional Surgery After Non-Curative Endoscopic Resection for Early Gastric Cancer? Long-Term Comparative Outcomes R3.
IMPACT OF STAGE MIGRATION ON NODE POSITIVE PROSTATE CANCER RATE AND FEATURES: A 20-YEAR, SINGLE INSTITUTION ANALYSIS IN MEN TREATED WITH EXTENDED PELVIC.
Professor Guram Karazanashvili MD, KMSc, DMSc MMT Hospital.
Surgical Management of Prostate Cancer
Papillary Thyroid Cancer Treated at the Mayo Clinic, 1946 Through 1970: Initial Manifestations, Pathologic Findings, Therapy, and Outcome  WILLIAM M.
Lymph Node Dissection for Renal Cell Carcinoma: When, How and Why?
Surgical Treatment in Locally Advanced Prostate Cancer
Professor Guram Karazanashvili MD, KMSc, DMSc MMT Hospital
Bladder Cancer and Prostatic Cancer
Oncological outcomes of high risk prostate cancer patients between robot-assisted laparoscopic radical prostatectomy and laparoscopic radical prostatectomy.
Alvin Y. Liu, Martine P. Roudier, Lawrence D. True 
Decipher Prostate, Decipher Bladder and Decipher GRID
New perioperative risk factors for biochemical recurrence after robotic assisted radical prostatectomy: A single surgeon experience in high volume Canadian.
RELAZIONE TRA “STAGE MIGRATION” E
Volume 131, Issue 4, Pages (April 2007)
RTOG 0126 A Phase III Randomized Study of High Dose 3D-CRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer Bijoy.
Post Op Positive Seminal Vesicle Case 4: Prostate_4
Prostate Cancer: Highlights from 2006
Development and internal-external validation of a multivariable prediction model for pre-operative assessment of positive lymph nodes during robot assisted.
Apollo Gleneagles Hospitals,
Advances in the Treatment of Metastatic Prostate Cancer
Volume 70, Issue 2, Pages (August 2016)
Volume 199, Issue 6, Pages (June 2018)
Volume 73, Issue 5, Pages (May 2018)
European Urology Oncology
Pitfalls of Pathologic Staging in Prostate Cancer
What is New in Hormone Therapy for Prostate Cancer in 2007?
Volume 73, Issue 2, Pages (February 2018)
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
LESLIE M. RAINWATER, M.D., WILLIAM R. MORGAN, M.D. 
Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer  Seong Yong Park, MD, Hyun-Sung Lee, MD, PhD, Hee-Jin Jang, MD, Geon Kook.
Papillary Thyroid Cancer Treated at the Mayo Clinic, 1946 Through 1970: Initial Manifestations, Pathologic Findings, Therapy, and Outcome  WILLIAM M.
Volume 70, Issue 2, Pages (August 2016)
Figure 1. Non-biochemical recurrence rate for the entire population (n = 122). From: Salvage radiation therapy for prostate cancer patients after prostatectomy.
Prostate Cancer Update
Volume 53, Issue 5, Pages (May 2008)
Management of Prostate Cancer: Global Strategies
Fernando P. Secin, Fernando J. Bianco, Nicholas T
Presentation transcript:

Memorial Sloan-Kettering Cancer Center Significance of and Techniques to Reduce the Frequency of Positive Surgical Margins James A. Eastham, MD Memorial Sloan-Kettering Cancer Center 353 East 68th Street New York, NY 10591 NOTE: The following slides are to be used for medical education purposes only. Copyright belongs to Prous Science and Prous Science is not responsible for any modification or change made by the users to these slides.

Index Definition of a positive surgical margin Significance of a positive surgical margin Surgical techniques to reduce the frequency of a positive surgical margin Key words: prostate, radical prostatectomy, surgical margin

Definition of a Positive Surgical Margin At the time of specimen processing, the outer surface of the radical prostatectomy is inked to define the margins of resection

Definition of a Positive Surgical Margin A positive surgical margin is defined as “tumor on ink”, meaning the pathologist sees cancer cells directly in contact with ink at histological examination Cancer cells abut the ink: positive margin

Significance of a Positive Surgical Margin Multiple series suggest that a positive surgical margin is an independent predictor of biochemical recurrence (BCR) after radical prostatectomy (RP)1-5 This risk remains even after controlling for other known risk factors for BCR after RP, including pre-treatment PSA, RP Gleason score, presence or absence of extraprostatic cancer, presence or absence of seminal vesicle invasion and presence or absence of lymph node invasion

Multivariable Analysis of Risk of 10-year Progression after Radical Prostatectomy1 HR (95%) CI p-value +SM 1.52 (1.06-2.16) 0.002 Gleason sum 1.82 (1.55-2.14) <0.0005 ECE 2.24 (1.56-3.22) SVI 2.54 (1.81-3.56) LNI 2.32 (1.60-3.37) n=1389 patients (1983-2000) +SM: Overall: 12.9%; pT2: 6.8%; pT3: 23%

Significance of a Positive Surgical Margin1 Even after controlling for other known risk factors of BCR after RP, a patient with a positive surgical margin is 1.5 times more likely to experience cancer recurrence than a patient with a negative surgical margin Of these clinical and pathological features, only the status of the surgical margins has the potential to be influenced by the surgeon

Significance of a Positive Surgical Margin Are positive surgical margins inherent in the nature of the cancer, like extracapsular extension, or can margins be influenced by the surgeon/surgical technique?

Surgeon’s Influence on the Likelihood of a Positive Surgical Margin2 Equal access medical center Academic and private practice urologists 4629 RP performed by 44 individual surgeons Question: What are the predictors of a positive surgical margin at the time of RP? Analysis included known clinical and histological variables as well as surgical experience (number of RP performed) and individual surgeon

Multivariable Analysis for Risk of a +SM Based on Clinical and Pathological Parameters2 p-value Serum PSA level < 0.01 Extracapsular extension Seminal vesicle invasion 0.86 Lymph node involvement 0.56 Radical prostatectomy Gleason sum Surgical volume 0.01 Surgery date Surgeon 0.05

Individual Surgeon and +SM Study2 The rate of +SM in RP specimens varies widely within and among hospitals and surgeons, whether at an open staffing hospital or a cancer referral center, and cannot be explained by surgical volume alone Wide variations in +SM rates persist even when corrected for all known cancer prognostic factors Differences in surgical technique, while hard to define, seem to result in substantial differences in positive margin rates and long-term cancer control rates

What Can Be Done to Decrease the Risk of a Positive Surgical Margin Exposure and hemostasis Appropriate extent of neurovascular bundle (NVB) preservation Wide dissection including Denonvilliers’ fascia, lateral pedicle and bladder neck

What Can Be Done to Decrease the Risk of a Positive Surgical Margin at Open RP? Exposure and hemostasis 8-10 cm lower midline incision Slight flexion of table Adequate retraction to expose the deep pelvis Author’s choice: Turner-Warwick retractor Appropriate extent of NVB preservation Wide dissection including Denonvilliers’ fascia, lateral pedicle and bladder neck

The patient is positioned supine with the pubis just below the break point in the table. The table is flexed (~150o) and Trendelenburg rotation is applied to level the abdomen. An 8-cm suprapubic midline incision is made 3 fingers breadth above the penis.

What Can Be Done to Decrease the Risk of a Positive Surgical Margin? Exposure and hemostasis Prior to division of the dorsal venous complex (DVC): suture-ligate the DVC at bladder neck, mid-prostate and pelvic floor Isolate DVC from urethra Author’s choice: right-angled clamp and stainless steel wire Divide DVC with knife and oversew cut-edge Appropriate extent of NVB preservation Wide dissection including Denonvilliers’ fascia, lateral pedicle and bladder neck

DVC ligated at bladder neck and mid-prostate

Division of the DVC over a guide wire. The DVC has been ligated proximally and distally. A right-angled clamp is passed beneath the DVC and grasps a wire. The DVC must be transected distal to all prostatic tissue. The right angle clamp is used to pass a 22 g guide wire beneath the DVC. The wire serves as a template for precise guillotine transection of the DVC. The DVC is first ligated distally with a figure-of-8 suture before it is divided. By adjusting downward traction on the prostate with a sponge stick and upward traction on the guidewire, the point of transection of the DVC can be adjusted to avoid incision into the prostate. While positive surgical margins are not common in this area, it is difficult to anticipate when cancer is located anteriorly.

The cut edges of the DVC are oversewn; the last bite being taken through the periosteum of the pubis

What Can Be Done to Decrease the Risk of a Positive Surgical Margin? Exposure and hemostasis Appropriate extent of NVB preservation Thorough assessment of risk of cancer in the area of the NVB Selection of appropriate plane of dissection Intra-, Inter- or Extrafascial dissection Wide dissection including Denonvilliers’ fascia, lateral pedicle and bladder neck

Endorectal MRI of prostate demonstrating the NVB and possible planes of dissection7, 10

Feet The extent of NVB preservation is a balance between attempts to optimize the recovery of potency while at the same time removing all the cancer (a negative surgical margin). The majority of screen-detected prostate cancers will be candidates for complete NVB preservation (intrafascial dissection). (R) Cavernous nerve Prostate Head

Apical Dissection with Nerve Sparing 1) Incision of lateral pelvic fascia above the nerve 2) Dissection of the NVB from apical third of the prostate 3) Sharp division of post layer of prostatorectal (Denonvilliers’) fascia The NVB should be dissected distally away from the apex and the proximal urethra. The posterior layer of Denonvilliers (prostatorectal) fascia also covers the NVB medially. This fascia must be divided, exposing the layer of adipose tissue anterior to the rectum, the correct plane of dissection. The posterior layer of the prostatorectal fascia should be left on the prostate to minimize the risk of a posterior positive margin.

Click on the link below to start the video. The initial mobilization of the NVB is complete. The scissors sharply incise Denonvilliers’ fascia exposing the yellow fat of the anterior rectal wall

Wide resection of the right NVB in the area of a large, palpable cancer. The dissection is facilitated by starting the dissection laterally such that all periprostatic tissue can be resected When cancer lies over the NVB, some or all of the bundle should be resected to assure a negative margin.

Transection of the Bladder Neck Wide dissection of the lateral pedicles around the base, and transection of the bladder neck above the prostate, will reduce the risks of positive margins. “Bladder neck preservation” does not improve continence. There should be ample tissue in the angle between the base of the prostate and the seminal vesicles. The bladder neck is transected proximal to the prostatic urethra to reduce the risk of a positive bladder neck margin. Preservation of the bladder neck does not improve long term continence. The specimen should contain abundant tissue in the angle between the base of the prostate and the seminal vesicles. Leave more tissue here

Conclusions Positive surgical margins are an adverse prognostic feature at the time of RP Of all prognostic factors, this is the only one modifiable by surgical technique Most patients can undergo preservation of the majority of the tissue at the NVB and still have complete resection of their cancer (negative surgical margin) Patient selection, complete resection of Denonvilliers’ fascia and wide resection at the bladder neck have been shown to reduce the incidence of a positive surgical margin

References Swindle, P., Eastham, J.A., Ohori, M., Kattan, M.W., Wheeler, T., Maru, N., Slawin, K., Scardino, P.T. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 2005, 174: 903-907. Eastham, J.A., Kattan, M.W., Riedel, E., Begg, C.B., Wheeler, T.M., Gerigk, C., Gonen, M., Reuter, V., Scardino, P.T. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol 2003, 170: 2292-2295. Karakiewicz, P., Eastham, J., Graefen, M., Cagiannos, I., Stricker, P., Klein, E., Cangiano, T., Schröder, F., Scardino, P., Kattan, M. Prognostic impact of positive surgical margins in surgically treated prostate cancer: Multi-institutional assessment of 5831 patients. Urology 2005,  66: 1245-1250. Ward, J.F., Zincke, H., Bergstralh, E.J., Slezak, J.M., Myers, R.P,, Blute, M.L. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol 2004, 172:1328-1332.

References Palisaar, R-J., Noldus, J., Graefen, M., Erbersdobler, A., Haese, A., Huland, H. Influence of nerve-sparing (NS) procedure during radical prostatectomy (RP) on margin status and biochemical recurrence. Eur Urol 2004, 47: 176-184. Eastham, J.A., Scardino, P.T. Radical prostatectomy for clinical stage T1 and T2 prostate cancer. In: Comprehensive Textbook of Genitourinary Oncology 2002, 722-738 (Ed. Vogelzang, N) Philadelphia: Lippincott Williams & Wilkins. Montorsi, F., Salonia, A., Suardi, N. Improving the preservation of the urethral sphincter and neurovascular bundles during open radical retropubic prostatectomy. Eur Urol 2005, 48: 938–945. Walsh, P.C., Partin, A.W., Epstein, J.I. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994, 152: 1831-1835.

References 9. Naya, Y., Slaton, J.W., Troncoso, P., Okihara, K., Babaian, R.J. Tumor length and location of cancer on biopsy predict side specific extraprostatic cancer extension. J Urol 2004, 171: 1093-1097. 10. Graefen, M., Walz, J., Huland, H. Open retropubic nerve-sparing radical prostatectomy. Eur Urol 2006, 49: 38–48.